Eli Lilly announced on Thursday that it will be implementing price increases for its medications in Europe and other developed markets in order to lower prices in the United States. This move is seen as a response to the Trump administration’s calls for pharmaceutical companies to decrease drug prices in the U.S. Specifically, Lilly highlighted the list price of its popular weight-loss drug in the United Kingdom as part of this initiative.
This decision by Lilly marks one of the first instances of a major drugmaker raising prices abroad with the intention of reducing prices domestically, aligning with President Trump’s push for lower drug costs. However, it remains uncertain whether these price adjustments will actually result in increased revenue for Lilly in international markets, as many governments and private providers negotiate discounts off list prices. At this time, Lilly has not announced any corresponding price reductions in the U.S.
One of the medications affected by this pricing strategy is Mounjaro, which is used for both diabetes and obesity in the U.K. The list price for the highest dose of Mounjaro will see an increase from £122 to £330, equating to approximately $165 to $447. In comparison, the list price for a month’s supply of Lilly’s weight loss drug, known as Zepbound in the U.S., is around $1,000.
It is important to note that the original article is restricted to STAT+ subscribers. To access the full content and receive daily coverage and analysis of the pharmaceutical industry, readers can subscribe to STAT+.
Overall, Lilly’s decision to adjust drug prices in international markets in order to offset costs in the U.S. reflects the ongoing debate surrounding drug pricing and access to affordable medications. As the pharmaceutical industry continues to navigate these challenges, it will be interesting to see how other companies respond and whether similar strategies will be implemented in the future.
